Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
ETR Entergy Corp
SKIN Beauty Health Co
PYR Pyrogenesis Canada Inc
KHZM Madison Ave Media Inc
PEO Adams Natural Resources Fund
MF Missfresh Ltd
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Closing Price
$33.23
Day's Change
1.45 (4.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.44
Day's Low
31.50
Volume
(Light)
Volume:
381,525

10-day average volume:
571,687
381,525

Cannabis debt holds up better than stocks in brutal 2022

12:17 pm ET June 30, 2022 (MarketWatch)
Print

By Steve Gelsi

Bond trader and commercial lender see debt tied to more solid cannabis names holding value but market is selective

While 2022 has been devastating for cannabis stocks amid lackluster prospects for federal legalization, debt prices in some larger U.S. cannabis companies have fared relatively well, market observers said.

Curaleaf Holdings Inc.' bonds have been yielding about 9.5% to 9.75% in 2022, up from about 8% at the end of 2021, according to market data.

Trulieve Cannabis Corp. has been yielding about 9% to 9.25%. The prices of the underlying debt have gone down in the low to mid 90% levels.

Trulieve ranked No. 1 among U.S. publicly traded cannabis companies with $318.3 million in first quarter revenue, followed by Curaleaf's $313.1 million. Green Thumb Industries , which generated $242.6 million in first-quarter revenue to win the No. 3 slot, has also held its pricing relatively well in the bond market.

Meanwhile, their stock prices have weakened dramatically in the face of interest rate hikes, recession jitters and heavy losses in the broad equities market. The Nasdaq is down 30% and the S&P 500 . The Global X Cannabis ETF (POTX) is down 55.5% and the AdvisorShares Pure U.S. Cannabis ETF (MSOS) has subtracted about 60%.

Curaleaf shares have fallen 46% in 2022 as of Thursday. Trulieve stock has moved down 56%. Green Thumb Industries is down 36.5%.

"As you go down the food chain of cannabis companies, the ones that are not as strong and large are not doing as well [in debt pricing]," said Jack Mascone, head of debt capital markets at Seaport Global Securities. "You're not going to see the same price resiliency in those players."

Capital raising is more difficult -- if not nearly impossible -- through the equities market with depressed stock prices, but capital remains available in the public and private debt markets, although at less favorable terms than in the past.

"With the right name and the right price and the right structure, there's still sufficient capital available, although the number of viable borrowers has gone lower," Mascone said.

Leonard M. Tannenbaum, founder and CEO of AFC Gamma Inc. (AFCG), a provider of institutional loans to cannabis operators secured by real estate, licenses and cashflow, said the cost of debt for cannabis companies has risen dramatically in 2022 along with higher interest rates across the lending world.

AFC Gamma remains more selective on providing loans and is gravitating toward better quality names, he said. The lender is currently avoiding cannabis companies in California and other states facing downward price pressure and competition from the illegal market, he added.

In the first 25 weeks of the year, cannabis companies raised $1.3 billion through 57 debt transactions, compared to $1.9 billion of debt raised in the year-ago period via 47 deals, according to Viridian Capital.

With cannabis companies stepping back from issuing stock to raise capital, debt comprised about 54% of total capital raised, its highest level in history for comparable levels, according to Viridian Capital's deal tracker for the week ended June 24.

This year's plunge in cannabis stock prices comes after measures such as the SAFE Banking bill to open up the financial system to cannabis companies have not made it through Congress, although talks continue to address it.

Other branches of the federal government have also been slow-moving such as the FDA's reluctance to regulate CBD.

Also Read: Trulieve, Ascend Wellness CEOs chart multi-state growth

-Steve Gelsi

	

(END) Dow Jones Newswires

June 30, 2022 12:17 ET (16:17 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.